§ 01 Overview
Overview
Mitochondrial protonophore that uncouples oxidative phosphorylation to increase metabolic rate without the cardiac risk profile of DNP.
Strong rodent data. Early human pharmacokinetic work; no large trials.
§ 02 Mechanism
Mechanism of action
BAM15 shuttles protons across the inner mitochondrial membrane, dissipating the proton gradient. This reduces ATP efficiency, forcing increased substrate oxidation and heat production, while showing a wider safety window than DNP in preclinical studies.
- 01Increased energy expenditure in preclinical models
- 02Reduced adiposity and hepatic steatosis in mice
- 03Safer window than DNP (preclinical)
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- Unknown; research doses small
- Route
- Oral
- Frequency
- Daily
- Cycle
- Not characterized
§ 04 Evidence
Evidence & research
Strong rodent data. Early human pharmacokinetic work; no large trials.
FDA Status
Not FDA-approved.
§ 07 Sourcing
Sourcing & supply
Regulatory status
Research-only, no commercial channel
No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Possible hyperthermia
- 02Tachycardia
- 03Insufficient human data
Contraindications
None specified.
§ 10 Questions
BAM15 FAQ
- What is BAM15?
- Mitochondrial protonophore that uncouples oxidative phosphorylation to increase metabolic rate without the cardiac risk profile of DNP. BAM15 shuttles protons across the inner mitochondrial membrane, dissipating the proton gradient. This reduces ATP efficiency, forcing increased substrate oxidation and heat production, while showing a wider safety window than DNP in preclinical studies.
- What is BAM15 used for?
- Reported uses include increased energy expenditure in preclinical models, reduced adiposity and hepatic steatosis in mice, and safer window than dnp (preclinical). Evidence strength is rated Preclinical — see the evidence section for detail.
- How is BAM15 dosed?
- Commonly referenced dosing is Unknown; research doses small, typically daily, administered Oral. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of BAM15?
- Commonly reported side effects include possible hyperthermia, tachycardia, and insufficient human data. This list is not exhaustive.
- Is BAM15 legal?
- No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established. FDA status: Not FDA-approved..